博纳吐单抗治疗复发或难治性急性淋巴细胞白血病成人患者的健康相关生活质量
3期TOWER研究显示,博纳吐单抗较标准化疗显著改善复发或难治性费城染色体阴性B细胞前体急性淋巴细胞白血病成人的总生存;本分析纳入405例随机患者中342例有基线及至少1次基线后EORTC QLQ-C30结果者,博纳吐单抗组(n=247)各子量表描述性均值变化普遍优于化疗组(n=95),除失眠、社会功能和经济困难外,至恶化时间风险比支持博纳吐单抗。
要点
- 博纳吐单抗组(n=247)各QLQ-C30子量表基线后描述性均值变化普遍优于化疗组(n=95)。
- 至HRQL恶化≥10分或死亡的风险比范围为0.42至0.81,支持博纳吐单抗。
- 除失眠、社会功能和经济困难外,其余指标风险比95%CI上限均<1.0。
核心结论
- 博纳吐单抗较化疗在复发或难治性费城染色体阴性B细胞前体急性淋巴细胞白血病成人中带来总生存和健康相关生活质量的临床有意义获益,支持其临床价值。
研究设计与样本
- 3期TOWER研究(NCT02013167)的次要分析,纳入405例随机患者中342例有基线及至少1次基线后EORTC QLQ-C30多条目量表或单条目测量结果者。
- 博纳吐单抗组247例,化疗组95例。
主要发现
- 基于基线描述性均值变化,博纳吐单抗组(n=247)在全部QLQ-C30子量表上报告的基线后HRQL普遍优于化疗组(n=95)。
- HRQL从基线恶化≥10分或死亡的时间至恶化风险比范围为0.42至0.81,支持博纳吐单抗,除失眠、社会功能和经济困难外所有指标95%CI上限<1.0。
- 不将死亡作为事件的HRQL时间至恶化敏感性分析与上述结果一致。
- 采用基于限制性最大似然的重复测量混合模型检验随时间治疗效果时,除经济困难外所有子量表测量博纳吐单抗对比化疗均达到P<.05。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the phase 3 TOWER study, blinatumomab significantly improved overall survival in adults with relapsed or refractory (R/R) Philadelphia chromosome-negative (Ph-) B-cell precursor acute lymphoblastic leukemia (BCP-ALL) relative to standard-of-care chemotherapy. A secondary objective of this study was to assess the impact of blinatumomab on health-related quality of life (HRQL) as measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30). This analysis included the 342 of 405 randomized patients for whom baseline and ≥1 postbaseline result were available in any EORTC multi-item scale or single-item measure. In general, patients receiving blinatumomab (n = 247) reported better posttreatment HRQL across all QLQ-C30 subscales, based on descriptive mean change from baseline, than did those receiving chemotherapy (n = 95). The hazard ratios for time to deterioration (TTD) of ≥10 points from baseline in HRQL or death ranged from 0.42 to 0.81 in favor of blinatumomab, with the upper bounds of the 95% confidence interval <1.0 across all measures, except insomnia, social functioning, and financial difficulties; sensitivity analysis of TTD in HRQL without the event of death were consistent with these findings. When treatment effect over time was tested using a restricted maximum likelihood-based mixed model for repeated measures analysis, P < .05 was reached for blinatumomab vs chemotherapy for all subscale measures except financial difficulties. The clinically meaningful benefits in overall survival and HRQL support the clinical value of blinatumomab in patients with R/R Ph- BCP-ALL when compared with chemotherapy. This trial was registered at www.clinicaltrials.gov as #NCT02013167.
引用
- Topp MS, Zimmerman Z, Cannell P, et al. Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab. Blood. 2018. PMID: 29739753. doi:10.1182/blood-2017-09-804658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。